On Thursday, Target Corporation (NYSE:TGT)’s shares declined -0.87% to $82.27.
CVS Health Corporation (CVS) and Target Corporation (TGT) declared that they have reached a definitive agreement for CVS Health to acquire Target’s pharmacy and clinic businesses for about $1.9 billion. Through this agreement, CVS Health will acquire Target’s more than 1,660 pharmacies across 47 states and operate them through a store-within-a-store format, branded as CVS/pharmacy. In addition, a CVS/pharmacy will be comprised of in all new Target stores that offer pharmacy services. Target’s nearly 80 clinic locations will be rebranded as MinuteClinic, and CVS Health will open up to 20 new clinics in Target stores within three years of the close of the transaction. The new clinics will be part of CVS/minuteclinic’s plan to operate 1,500 clinics by 2017. In addition, CVS Health and Target plan to develop five to 10 small, flexible format stores over a two-year period following the deal close, which will each be branded as TargetExpress and comprise a CVS/pharmacy.
Target Corporation operates as a general merchandise retailer in the United States and Canada. It offers household essentials, counting pharmacy, beauty, personal care, baby care, cleaning, and paper products; music, movies, books, computer software, sporting goods, and toys; electronics, such as video game hardware and software; and apparel for women, men, boys, girls, toddlers, infants, and newborns, in addition to intimate apparel, jewelry, accessories, and shoes.
Atmel Corporation (NASDAQ:ATML)’s shares dropped -0.41% to $9.71.
Atmel® Corporation (ATML), a global leader in microcontroller (MCU) and touch solutions, recently declared that the company is powering the borderless nubia Z9 smartphone with its award-winning maXTouch® T-series solution.
In recently smartphone market, next-generation industrial designs and new display technologies are key differentiating factors that OEMs require to set their designs apart from their competition. Atmel’s unique, proprietary single-layer pattern brings a true borderless and futuristic industrial design for tomorrow’s handsets. The maXTouch mXT336T delivers these features, together with advanced algorithms and Atmel’s adaptive sensing technology to enable virtual edge keys and sliders—delivering interaction all the way to the edge of the phone. These features enable OEMs to develop new UI concepts, revolutionizing the way users interact with their smartphones.
Atmel’s mXT336T supports up to 10 touches with wake-up gesture libraries and best in-class calibration recovery to enable robust touch performance and excellent noise immunity for recently after-market chargers in extremely noisy environments.
Atmel Corporation designs, develops, manufactures, and sells semiconductor integrated circuit products primarily in the United States, Asia, Europe, South Africa, and Central and South America. It operates in four segments: Microcontroller, Nonvolatile Memory, Automotive, and Multi-Market and Other. The Microcontroller segment provides various proprietary and non-proprietary architectures, such as AVR 8-bit and 32-bit, ARM-based, Atmel’s 8051 8-bit, and low power radio and SOC products, in addition to capacitive touch products, counting maXTouch and QTouch. The Nonvolatile Memory segment offers electrically erasable programmable read-only and erasable programmable read-only memory devices, in addition to secure cryptographic products.
At the end of Thursday’s trade, Phillips 66 (NYSE:PSX)‘s shares surged 0.16% to $81.43.
Phillips 66(PSX) will release its second-quarter 2015 financial results Friday, July 31, at 8 a.m. EDT. Later that day, Phillips 66 executive administration will host a conference call webcast at noon EDT to talk about the company’s second-quarter performance and provide an update on planned initiatives.
Phillips 66 operates as an energy manufacturing and logistics company. It operates through four segments: Midstream, Chemicals, Refining, and Marketing and Specialties (M&S). The Midstream segment transports crude oil and other feedstocks to its refineries and other locations; and delivers refined and specialty products, in addition to provides storage services for crude oil and petroleum products.
Applied Genetic Technologies Corp (NASDAQ:AGTC), ended its Thursday’s trading session with 17.04% gain, and closed at $19.03.
Biogen (BIIB) and AGTC (AGTC) declared a broad partnershipand license agreement to develop gene-based therapies for multiple ophthalmic diseases. The partnershipwill focus on the development of a portfolio of AGTC’s therapeutic programs, counting both a clinical stage candidate and a pre-clinical candidate for orphan diseases of the retina that can lead to blindness in children and adults. The agreement also comprises options for early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition, in addition to an equity investment in AGTC by Biogen and a license agreement for manufacturing rights.
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
